Complix receives €1.9 million IWT grant to accelerate development of Alphabodies™ against intracellular disease targets, including cancer
Complix announces that it has been awarded a €1.9 million grant (approximately USD$2.4 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in Flanders). The grant will allow Complix to accelerate the development of its unique cell penetrating Alphabodies (CPABs), against a range of intracellular disease targets, including cancer.
MONSANTO COMPANY AND COMPLIX SIGN COLLABORATION TO BRING NEW TECHNOLOGIES TO AGRICULTURE
ST. LOUIS and HASSELT, BELGIUM (September 20, 2012) – Monsanto Company and Complix NV today announced they have entered into a collaboration agreement to evaluate and develop Complix's proprietary Alphabody® protein technology in the field of agriculture.
Complix' Alphabody™ Protein Therapeutics Demonstrate Activity against both Undruggable Extracellular and Intracellular Disease Targets
Hasselt, April 26, 2012 – Complix NV, a biopharmaceutical company focused on the discovery and development of Alphabodies, a unique class of protein therapeutics that are active against both extracellular and intracellular disease targets, announces that it will provide an update on new developments with its Alphabody™ platform at the Biologics Partnering Forum in Boston, MA on 29 April 2012.
IAVI and Belgium-Based Biotech Complix NV Partner on a Novel Approach to HIV Vaccine Design
New York, USA and Hasselt, Belgium March 19, 2012 — The International AIDS Vaccine Initiative (IAVI) and Complix NV today announced a new collaboration to apply a novel approach to understanding the structure of a critical piece of the HIV Envelope protein complex. This collaboration will help advance the development of HIV vaccine candidates that can generate broadly neutralizing antibodies—molecules capable of neutralizing a broad spectrum of variants of HIV — a key priority in AIDS vaccine development.
Complix selects first Alphabody™ development candidate
Complix NV announced today that it has progressed its first Alphabody™ product, CMPX-1023, into preclinical development. CMPX-1023 is under development for treatment of autoimmune diseases and inflammation. Complix has achieved this important milestone less than 12 months after starting the discovery program for this compound, illustrating the efficiency of its proprietary Alphabody™ discovery engine. CMPX-1023 is Complix´s first Alphabody™ entering the development phase. Complix has other ongoing discovery programs for Alphabody™ therapeutics against autoimmune and viral diseases.
Complix appoints Dr Thore Hettmann as Head of Therapeutic Development
Dr Hettmann has more than 10 years experience in the biotech industry, with an excellent track record in the successful progression of biopharmaceutical product candidates into the clinical stage. At Complix he will be responsible for the preclinical and early clinical development of new Alphabody™ leads emerging from the discovery pipeline.
Complix will be presenting at BioPharm America, September 7-9, 2011 in Boston
At this major industry business event in the U.S. where pharma, biotech and decision makers meet, Complix will share the latest developments on its anti-viral and anti-inflammatory programs. The company has made significant progress in advancing its first Alphabody™ therapeutics through the pre-clinical phase. Expect to hear news about Complix´s pipeline with RSV, HIV and Influenza Alphabodies, as well as its lead compound in development for auto-immune disease indications.
If you would like to schedule a meeting with us at BioPharm America, you can do so through the online partnering system or by sending us a request at email@example.com.
Complix extends Series A financing to EUR 7 million with Crédit Agricole
Complix announces that it has raised an additional EUR 2 million from leading life sciences investor Crédit Agricole Private Equity (Paris, France) as part of an extension of its Series A equity financing round, bringing the total amount of this round to EUR 7 million. Emmanuelle Coutanceau, PhD, from Crédit Agricole Private Equity is joining the Complix Board of Directors.
Complix receives EUR 1.6 million IWT grant to accelerate development of therapeutic Alphabodies™
Complix announces that it has been awarded a EUR 1.6 million grant (approximately USD 2.1 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in Flanders). In June of this year Complix already raised EUR 5 million in equity financing to fund its preclinical development programs based on therapeutic Alphabodies™. The present funding by IWT, which covers a period of 2 years, will allow Complix to accelerate the development of its lead Alphabody™ product for treatment of autoimmune diseases.
Complix presents at BIO-Europe 2010
On 17 November 2010, Dr. Mark Vaeck, CEO, presented the latest company progress at the BIO-Europe 2010 partnering conference in Munich. Click "more" for a copy of the slide deck.
Complix Luxembourg S.A. receives financial contribution from the Ministry of Economy and Foreign Trade.
On 29 July 2010, Complix Luxembourg S.A., a wholly owned subsidiary of Complix N.V., entered into an agreement with the Ministry of Economy and Foreign Trade of the Grand Duchy of Luxembourg. As part of the agreement, Complix Luxembourg S.A. will receive a significant financial contribution to accelerate its research and product development efforts.
Complix: Scaffolds with a twist
BioCentury, 6 september 2010 -
Complix N.V. believes the protein scaffolds created with its Alphabody technology will have greater stability and diversity than therapeutics based on other protein scaffolds. The resulting therapeutics could bind their targets with greater affinity than other types of proteins, and the company expects Alphabodies to be amenable to routes of administration other
Complix raises € 5 million in series A equity financing for the development of Alphabody™ therapeutics
Hasselt, Belgium – June 3rd, 2010 - Complix NV, a recently founded biopharmaceutical company, announced the successful closing of its Series A financing round, raising € 5 million (~US$ 6.25 million) from a syndicate of leading life sciences investors.